超声引导下经直肠前列腺穿刺活组织检查术在前列腺癌诊断中的意义

目的:探讨超声引导下经直肠前列腺穿刺活组织检查术在前列腺癌诊断中的意义。方法:选取2013年2月~2015年2月北京怀柔医院收治的280例患者为研究对象,回顾性分析其临床资料,经直肠前列腺穿刺活组织检查其超声显像结果与病理资料,并分析影响前列腺癌诊断的相关因素。结果:本组280例患者,前列腺癌检出率为39.64%(111/280),根据患者年龄分为4组,组间前列腺癌检出率比较,差异有统计学意义(P0.05);240例检测前列腺特异性抗原(Prostate specific antigen level,PSA)水平患者,前列腺癌检出率为34.17%(82/240),根据PSA分为5组,组间前列腺癌检出率比较,差异有统计学意义(P0.05);248例经直肠超声检查前列腺体积患者,前列腺癌检出率为37.90%(94/248),根据前列腺体积分为2组,组间前列腺癌检出率比较,差异有统计学意义(P0.05)。结论:在疑似前列腺癌诊断中应用超声引导下经直肠前列腺穿刺活组织检查术,具有积极的意义,临床价值显著。     

经直肠实时组织超声弹性成像诊断前列腺良恶性病灶的价值

目的:探索经直肠实时组织超声弹性成像技术在前列腺良恶性病灶诊断中的应用价值。方法:选取2013年12月至2014年5月我科疑似前列腺癌(PCa)并拟行穿刺活检的患者49例,以病例活检结果作为金标准,对比经直肠实时组织超声弹性成像技术、经直肠超声(TRUS)及直肠指诊(DRE)在疑似PCa患者中的诊出结果,并对直肠超声进行弹性图像评分及应变指数分析。结果:弹性图像评分≥4分时,其对PCa的敏感性、特异性及准确性分别为92.3%、91.3%和93.9%;良性病灶的应变指数为2.84±4.72,恶性病灶的应变指数为32.12±15.05,差异有统计学意义(P0.05)。结论:经直肠实时组织超声弹性成像技术可提高PCa的诊出率,在前列腺良恶性病灶的鉴别及指导治疗与预后方面有重要价值。     

血糖与前列腺癌患者的关系

目的:探讨前列腺活检患者的血糖与前列腺癌患者的关系。方法:前瞻性收集416例初次经直肠超声引导下前列腺穿刺活检患者的血糖、前列腺特异性抗原(PSA)和Gleason评分等临床资料,所有患者以血糖浓度6.1 mmol/L为界分成两组,比较高血糖组和正常血糖组前列腺癌检出率和Gleason评分的差异。结果:416例前列腺活检患者中,检出前列腺癌165例,高血糖组38例(40.00%),正常血糖组127例(39.56%),差异无统计学意义(P0.05);低级别前列腺癌(Gleason7分)患者的构成比分别为0.184、0.071,差异有统计学意义(P0.05),Spearman等级相关分析显示前列腺癌患者的血糖值与Gleason评分呈负相关(r=-0.228,P0.05)。结论:血糖对前列腺活检患者中前列腺癌检出率没有影响,但提高了低级别前列腺癌患者的构成比,血糖是影响前列腺癌Gleason评分的一个独立因素。     

影像引导下前列腺定向穿刺活检术的研究进展

确诊前列腺癌的金标准无疑是病理组织学检查,影像引导下的前列腺定向穿刺活检又是这当中最有效、最便捷的方式。而基于前列腺特异抗原(prostate specific antigen,PSA)筛查以及6分活检结果的前列腺癌诊断,已经由于其对低度肿瘤的过度诊断和对临床上有意义前列腺癌(格林森评分≥7)的诊断不足遭到批评。所以纵观国内外,影像引导已经增加到先用多参数MRI(multi-parametric magnetic resonance imaging,mpMRI)扫描检出病变组织再进行前列腺定向穿刺活检,包括,in-bornMRI引导,认知融合引导,以及MRI/TRUS融合引导下的活检。本文就一些影像引导下前列腺定向穿刺活检术的研究进展进行综述。     

经直肠前列腺穿刺活检术后败血症的相关因素分析

目的:虽然前列腺穿刺活检术前预防及术后治疗都有了很大的创新,但术后的并发症仍可能发生,本文通过对前列腺穿刺术后感染性并发症的前瞻性检测,对其致病菌进行描述,探讨经直肠前列腺穿刺活检术后败血症的发生率、致病菌、发病相关因素,为临床上败血症的治疗和预防提供理论依据。方法:对2008年1月-2012年11月在兰州军区总医院经直肠前列腺穿刺活检术后238例患者中6例尿路败血症患者进行回顾性分析及术后随访。结果:经直肠前列腺穿刺活检术后并发败血症占2.52%(6/238),8例败血症患者中感染性休克患者3例。血培养阳性6例,5例为大肠埃希菌,1例为耐甲氧西林金葡菌。结论:经直肠前列腺穿刺是简单有效的活检方式,但仍有发生败血症的可能,致病菌多为大肠埃希菌。术前适当准备及术后合理预防可减少并发症的发生。如患者前列腺穿刺活检术后48 h内出现败血症的症状,则应立即入院给予碳青霉烯类治疗。多重耐药大肠埃希菌感染要引起足够重视,早期的直肠及尿液耐药大肠埃希菌检查可有助于败血症的早期预防。     

前列腺癌患者前列腺体积与肿瘤分级之间关系探讨

目的:探讨国人前列腺癌患者前列腺体积与肿瘤分级之间的关系。方法:回顾我院及武汉大学人民医院2005年1月-2011年10月70例确诊为前列腺癌并行根治性前列腺切除术(RP)患者的临床病理资料,采用SPSS13.0软件总结并分析前列腺癌患者前列腺体积与肿瘤分级之间的关系。结果:经直肠前列腺穿刺活检获得肿瘤病理分级与根治性前列切除术获得最终病理分级具有显著差异(P=0.003);在活检及根治性前列腺切除标本中,前列腺体积与高级别肿瘤发生率均呈负相关(P<0.05);小前列腺与阳性手术切缘、前列腺外侵犯及高级别肿瘤在单变量分析中具有相关性(P<0.05),而与精囊腺侵犯及淋巴结侵犯则无相关性(P>0.05);在校正了年龄、体重指数及术前前列腺特异性抗原水平后,前列腺体积与阳性手术切缘、前列腺外侵犯、精囊腺侵犯及高级别肿瘤发生率均呈负相关(OR<1,P<0.05),而与淋巴结侵犯则无相关性(P>0.05)。结论:前列腺体积是高级别前列腺癌的重要预测因子,利用其对高级别肿瘤风险的预测能力可帮助选择最佳治疗方案并进一步提高治疗效果。     

血清PSA含量与前列腺癌临床分期、病理分级的相关性

目的:探讨血清前列腺特异性抗原(PSA)与前列腺癌(PCa)临床分期、病理分级的相关性.方法:对自2004年7月～2009年12月南京市13692例50岁以上的男性在健康体检时行血清PSA检测.以PSA≥4.0ng/ml定为前列腺癌可疑病例.建议行前列腺穿刺活检以确诊.共筛查出PCa患者140例,比较不同PSA值PCa患者的Gleason评分及临床分期.结果:随着PSA值的升高,前列腺癌筛查阳性率亦随之升高,低分化前列腺癌患者血清PSA含量明显高于高分化前列腺癌和中分化前列腺癌患者(P＜0.05),晚期前列腺癌患者血清PSA含量明显高于早期PCa患者(P＜0.01).血清PSA含量≥20ng/ml的前列腺癌人群中低分化前列腺癌及晚期前列腺癌的比例高于血清PSA含量＜20ng/ml的前列腺癌人群(P＜0.01).结论:血清PSA可以为前列腺癌患者的诊断、治疗及预后判断提供重要依据.     

系统活检联合超声造影及弹性成像靶向活检在前列腺活检中的应用价值

摘要 目的：探讨系统活检联合超声造影及弹性成像靶向活检在前列腺活检中的应用价值。方法：回顾性分析2015年1月至2019年12月我院收治的394例可疑前列腺癌患者的临床资料。分为前期组（2015年1月至2017年4月,采用12针系统活检法,共186例）,和近期组（2017年5月至2019年12月,采用8针系统活检联合新技术（超声造影及弹性成像）靶向活检法,共208例）。前期组行12+X针系统穿刺活检。近期组患者先行彩虹灌注及实时弹性成像检查,确定可疑区域后,于该区域行靶向穿刺活检,然后行8针系统穿刺活检,有重复区域者适当减少穿刺针数。结果：近期组阳性患者99例;前期组阳性患者63例,前列腺癌检出率分别为47.6%（99/208）、33.87%（63/186）,差异具有统计学意义（P<0.05）;近期组与前期组总穿刺针数分别为1929、2200针,近期组平均9.0 1.8针,前期组平均11.8 1.6针,差异具有统计学意义（P<0.05）;近期组与前期组穿刺针数阳性率分别为23.89%（461/1929）、11.82%（260/2200）,差异具有统计学意义（P<0.05）;近期组与前期组并发症发生率分别为27.40%（57/208）、43.01%（80/186）,差异具有统计学意义（P<0.05）。结论：系统活检联合超声造影及弹性成像靶向活检对前列腺癌具有较高应用价值。     

超声引导经皮肺肿块穿刺活检在临床诊断中的应用

应用超声引导经皮自动穿刺活检术对79例经X线及CT检查发现肺部肿块患者进行穿刺活检,分析患者穿刺活检二维声像图特征,彩色血流信息特征,病灶内造影剂增强情况,穿刺活检成功率及并发症情况,探讨超声引导经皮肺肿块穿刺活检在肺肿块病变临床诊断中的应用价值。结果发现:实验组79例患者中,周围型肿块73例,中央型肿块伴肺实变6例,恶性病变60例,良性病变19例。恶性病变病灶回声类型、病灶最大径线、Adler血量分级、病灶内造影剂均匀性与良性病变同类指标比较具有显著差异性(p0.05)。可见:超声引导经皮肺肿块穿刺活检是安全可靠,简便易行的方法,其良、恶性病变二维声像图特征,彩色血流信息特征,病灶内造影剂增强情况差异显著,在肺周围型肿块及伴实变中央型肿块患者的病理分型诊断中具有重要的应用价值。     

根治性前列腺切除术后大体病理较术前穿刺病理升级的危险因素分析

目的:前列腺穿刺病理Gleason评分(GS)和根治性前列腺切除术后病理Gleason评分经常出现差异.本文主要研究肿瘤病理升级的可能影响因素.方法:选择1999-01至2007-11在本院行前列腺穿刺活检确诊并行根治性前列腺切除术的95例前列腺癌患者,考察的临床资料包括患者确诊时的年龄,前列腺特异性抗原水平(PSA),前列腺体积(PV),前列腺特异性抗原密度(PSAD),术前是否接受新辅助内分泌治疗(NHT),穿刺病理GS,手术后病理GS及肿瘤体积(TIV).使用t-检验或卡方检验比较不用组别之间的变量,分别使用单因素和多因素Logistical回归分析引起GS升级的相关因素.结果:患者的平均年龄是67岁,平均PSA水平为24.3 ng/ml,平均前列腺体积是33.1ml.将前列腺体积分为≤25ml(25例),25-50ml(59例),≥50ml(11例)三组,将穿刺病理GS分为4-5(13例),6(35例),7(32例),8-10(15例)四组.前列腺体积较大组(≥50m1)比体积较小组(≤25ml,25-50m1)的肿瘤升级比率明显较低(48% vs 24%,18%,p＜0.05).穿刺病理GS较高组(8-10)比较低组(4-5,6,7)的肿瘤升级比率明显减低(46% vs 34%,25%,13%,p＜0.05).多因素Logistic回归分析显示,PV、穿刺GS及内分泌治疗与病理升级呈负相关(p＜0.05),而肿瘤体积及PSAD与其呈正相关(p＜0.05).结论:较大的前列腺体积,较高的穿刺病理GS,接受内分泌治疗以及较低的PSAD均可降低其肿瘤升级的可能.泌尿外科医师在决定由穿刺活检确诊的前列腺癌患者的治疗方案时应想到上述结论.     

Role of screening in detection of clinically localized prostate cancer

The aim of this study was to confirm the role of screening by determining the percentage of clinically localized prostate cancer (stage A and B) in patients with prostate cancer detected on screening and in those presenting to urologic clinic for the symptoms of urination impairment or ostalgia. During the study, 1,000 men aged > or = 50 from the community of Cepin and village of Josipovac near Osijek were examined. The subjects with elevated concentration of total prostate specific antigen and/or digital rectal examination suspect of carcinoma underwent transperineal biopsy of the prostate. Clinical staging was performed in patients with prostate cancer detected on screening, and data on clinical staging for prostate cancer patients treated during the 1996-1997 period were retrieved from patient files of the Department of Urology, University Hospital "Osijek". On screening, 28 (80%) patients with localized prostate cancer and seven (20%) patients with metastases were detected. In the group of patients examined on an outpatient basis for the signs and symptoms of prostatism, there were 30 (83.4%) patients with metastases and only six (16.6%) patients with localized prostate cancer. Study results indicated that an early diagnosis of prostate cancer could be made by use of noninvasive and inexpensive methods that cause no major discomfort to the patient. Accordingly, these results appear to strongly support such screening in men, if not in all those aged over 50, then at least in the otherwise healthy, 50-70 age group.     

Fine needle aspiration cytology of granulomatous prostatitis induced by BCG immunotherapy of bladder cancer

Six patients treated with intravesical bacillus Calmette-Guérin (BCG) for superficial bladder cancer had granulomatous prostatitis demonstrated histologically by transperineal needle biopsy. Four of the six patients also underwent transrectal fine needle aspiration (FNA) for cytologic study. The diagnosis of granulomatous prostatitis was made cytologically in all four without knowledge of the histologic findings. Granulomatous prostatitis appears to be common following intravesical BCG treatment; these cases show that FNA cytology can be recommended as a method for diagnosing this complication.     

Transrectal sonography in prostate cancer detection--our 25 years experience of implementation

Prostate cancer is a leading public health problem of male population in developed countries. Gold standard for prostate cancer diagnosis is true cut biopsy guided by transrectal ultrasound. Aim of this study was to determine sensitivity, specificity, accuracy, positive and negative predictive value of transrectal sonography (TRUS) in prostate cancer detection. The analysis was made for two time periods, before and after routine implementation of prostate specific antigen (PSA) in prostate cancer diagnostics. From 1984 to 1993 TRUS guided prostate biopsy was performed in 564, and from 1994 to 2008 in 5678 patients. In the second period PSA was routinely used in prostate cancer diagnostics. In the first period by TRUS we have made an exact diagnosis of prostate cancer in 18.97% of patients what was confirmed by biopsy. 4.61% ware false positive and 11.34% ware false negative. In the second period prostate cancer was recognized in 30.34% of patients, confirmed by biopsy. False positive cases ware 6.11% and false negative 29.31%. Sensitivity of transrectal sonography in the first period was 62.57%, specificity 94.2%, accuracy 86.2%, positive predictive value 80.45% and negative predictive value 87.72%. In the second period sensitivity was 50.87%, specificity 91.93%, accuracy 73.84%, positive predictive value 83.24% and negative predictive value 70.39%. Based on our experience we can conclude that prostate cancer is mostly found in the peripheral zone. Smaller tumors are hypoechoic and bigger tumors are hyperechoic. Prostate cancer lesions are impossible to differentiate from chronic prostatitis only by TRUS. Implementation of PSA has significantly decrease sensitivity, accuracy and negative predictive value of TRUS in prostate cancer detection. TRUS guided true cut biopsy is a gold standard in prostate cancer diagnostics.     

Transperineal prostate biopsy: analysis of a uniform core sampling pattern that yields data on tumor volume limits in negative biopsies

Background  

Analyze an approach to distributing transperineal prostate biopsy cores that yields data on the volume of a tumor that might be present when the biopsy is negative, and also increases detection efficiency.     

Finding of no tumor (pT0) in patients undergoing radical retropubic prostatectomy for clinically localized prostate cancer

OBJECTIVE: To evaluate features and clinical outcome of patients with clinically localized prostate cancer graded pT0 following radical retropubic prostatectomy (RRP). STUDY DESIGN: Between 1974 and 2001 we performed 1,135 RRPs for cT1-T2 prostate cancer, of which 386 (34%) underwent 3-6 months of neoadjuvant endocrine treatment (NHT) before RRP. Median clinical follow-up was 53.8 months (range 24-251). Estimation of likelihood events for biochemical relapse was calculated according to the Kaplan-Meier method. Statistical differences between curves were calculated using the log-rank test. RESULTS: In 24 cases (2.12%) routine histologic workup failed to detect residual tumor. The pT0 group contained a higher proportion of cTla-b patients and a biopsy Gleason score < or =6. A tendency toward lower pre-operatory PSA levels in the pT0 group compared to the pT2-3 group was shown. PSA progression was observed in 3 pT0 patients, all of whom previously underwent NHT. CONCLUSION: Patients pT0 at RRP presented with lower preoperative PSA values and low preoperative Gleason score compared to the pT+ group. Absence of tumor at pathology examination has a different clinical meaning when it occurs following NHT or in untreated patients. Patients pT0 after NHT may have a worse clinical outcome than pT0 untreated patients.     

Advances in brachytherapy

During the past 15 years, permanent seed brachytherapy for prostate cancer has advanced significantly in all areas, including patient selection, treatment planning, technique, and technology (eg, seeds stranded in Vicryl suture). These improvements have made transperineal seed implantation an accurate and practical treatment option for men with low-, intermediate-, and high-risk disease. Because of the evidence that the various treatment options for prostate cancer are likely to be equally successful in terms of long-term cancer control, continuing efforts focus on enhancing the quality of life of implant patients.     

Comparison of digital rectal examination and prostate specific antigen in early detection of prostate cancer

This study compares the value of digital rectal examination (DRE) and prostate specific antigen (PSA) determination in the detection of prostate cancer. 1,000 men aged > or = 50 from the Osijek surroundings were examined. The subjects with prostatitis were excluded from the study. The subjects with elevated concentration of total prostate specific antigen and/or digital rectal examination suspect of carcinoma underwent prostate biopsy. The rate of prostate cancer detection showed to be 3.3% for PSA > 4 ng/ml, 2% for abnormal finding of DRE, and 3.7% for combination of the two methods. Out of 35 patients with prostate cancer detected, 19 had suspect DRE finding and 32 had PSA exceeding 4 ng/ml. Thus, PSA pointed to the diagnosis of prostate cancer in 91.4%, and abnormal finding of DRE in 54.2% of cases, the difference being statistically significant. The positive predictive value was 48.7% for abnormal finding of DRE, 47% for PSA > 4 ng/ml, and 80.0% for the combination of both. Although PSA determination detected a considerable proportion of tumors missed on DRE, the former alone was found to be insufficient as a screening method because of its inadequate sensitivity. When combined with digital rectal examination, the probability of prostate cancer detection increased considerably.     

Repeat Prostate Biopsy Strategies after Initial Negative Biopsy: Meta-Regression Comparing Cancer Detection of Transperineal,Transrectal Saturation and MRI Guided Biopsy

Introduction

There is no consensus on how to investigate men with negative transrectal ultrasound guided prostate biopsy (TRUS-B) but ongoing suspicion of cancer. Three strategies used are transperineal (TP-B), transrectal saturation (TS-B) and MRI-guided biopsy (MRI-B). We compared cancer yields of these strategies.

Methods

Papers were identified by search of Pubmed, Embase and Ovid Medline. Included studies investigated biopsy diagnostic yield in men with at least one negative TRUS-B and ongoing suspicion of prostate cancer. Data including age, PSA, number of previous biopsy episodes, number of cores at re-biopsy, cancer yield, and Gleason score of detected cancers were extracted. Meta-regression analyses were used to analyse the data.

Results

Forty-six studies were included; 12 of TS-B, 14 of TP-B, and 20 of MRI-B, representing 4,657 patients. Mean patient age, PSA and number of previous biopsy episodes were similar between the strategies. The mean number of biopsy cores obtained by TP-B and TS-B were greater than MRI-B. Cancer detection rates were 30·0%, 36·8%, and 37·6% for TS-B, TP-B, and MRI-B respectively. Meta-regression analysis showed that MRI-B had significantly higher cancer detection than TS-B. There were no significant differences however between MRI-B and TP-B, or TP-B and TS-B. In a sensitivity analysis incorporating number of previous biopsy episodes (36 studies) the difference between MRI-B and TP-B was not maintained resulting in no significant difference in cancer detection between the groups. There were no significant differences in median Gleason scores detected comparing the three strategies.

Conclusions

In the re-biopsy setting, it is unclear which strategy offers the highest cancer detection rate. MRI-B may potentially detect more prostate cancers than other modalities and can achieve this with fewer biopsy cores. However, well–designed prospective studies with standardised outcome measures are needed to accurately compare modalities and define an optimum re-biopsy approach.